Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Baeocystin is a **small-molecule serotonergic tryptamine alkaloid** and a structural analogue of psilocybin that is being developed by **Pilz Bioscience** under the code name **PLZ-1019**. It has been described as a **5-hydroxytryptamine receptor 2A agonist** and is thought to function largely as a **prodrug of norpsilocin**, a centrally penetrant active metabolite with potent serotonin receptor activity. Baeocystin occurs naturally as a minor constituent of psilocybin-containing mushrooms and is currently reported to be in **discovery-stage development** for **pervasive developmental disorders such as autism in children**.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on baeocystin.